Bevin M.B. Newman

Sheppard Mullin (Washington)
Lawyer (Partner)

Bevin Newman is a partner in the Antitrust and Competition Practice Group in the Washington, D.C. office of Sheppard Mullin. Areas of Practice Bevin is a strategic adviser to clients in cutting-edge affiliations and collaborative arrangements. She focuses much of her practice in the healthcare industry, bringing over 20 years of experience advising and defending globally renowned health systems, academic medical centers, providers, payers and pharmaceuticals companies undertaking significant transactions, including mergers and acquisitions, joint ventures, intellectual property licenses and innovative alliances, as well as on conduct matters. She represents clients before the Federal Trade Commission, the Department of Justice and state attorneys general on complex antitrust matters. Bevin also has extensive experience coordinating the merger-control, foreign direct investment (CFIUS) and regulatory reviews of multi-jurisdictional transactions for U.S. and foreign clients in the pharmaceutical, medical device, technology and energy industries. She is one of the most experienced Hart-Scott-Rodino Act (HSR Act) practitioners in the country. She has advised on multiple antitrust matters for Caremark, Cigna, UPMC, Duke University, Yale-New Haven Health System, Centura, SSM Health, UnityPoint, Abbot Laboratories, Boehringer Ingelheim, Sumitomo Dainippon Pharmaceuticals and Bon Secours Mercy Health. Bevin frequently writes and speaks on antitrust and competition issues, particularly in the healthcare field. Her publications include Antitrust Aspects of Mergers and Acquisitions (BNA Corp. Practice Series) and "An Overview of Federal Antitrust Laws and Enforcement Policies" (CCH Health Care Compliance Professionals Manual). She served on the editorial board for the ABA’s Antitrust Compliance and is a member of the Antitrust and Health Law Sections of the ABA and Antitrust Section of the American Health Lawyers Association.

Distinctions

Linked authors

Jones Day (Houston)
Jones Day (Washington DC)
Jones Day (Washington DC)
Jones Day (Beijing)
Gibson Dunn (Hong Kong)
Jones Day (Beijing)
Winston & Strawn (New York)
Dentons (Tysons Corner)

Articles

4132 Bulletin

Leo Caseria, Robert L. Magielnicki, Malika Levarlet, Bevin M.B. Newman The US FTC introduces temporary electronic HSR filing and stops granting early terminations for all filings due to COVID-19 measures

57

In response to COVID-19, the FTC’s Premerger Notification Office (PNO) just announced several changes for all Hart-Scott-Rodino (HSR) filings going forward. While these changes have been described as temporary, no specific end date has been identified. Hard copy HSR filings will no longer be (...)

Bevin M.B. Newman, Geoffrey D. Oliver, Michael Sennett The Court of Appeal for the District of Columbia rejects a challenge to an FTC rule that makes the HSR Act reporting requirements cover pharmaceutical patent licenses that transfer all commercially significant rights (PhRMA)

177

The D.C. Circuit has rejected a challenge by the Pharmaceutical Research and Manufacturers of America ("PhRMA") to an FTC rule that makes the HSR Act reporting requirements cover pharmaceutical patent licenses that transfer "all commercially significant rights." The rule, adopted in 2013, (...)

Bevin M.B. Newman, Toby G. Singer The US FTC agrees to require only minor behavioral remedies and no structural remedies in a hospital merger case highly unusual due to state laws applicable to hospitals (Phoebe Putney Health System)

211

This article has been nominated for the 2014 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. The U.S. Federal Trade Commission has settled its long running dispute with the Phoebe Putney Health System, Palmyra Park Hospital, and the Hospital Authority of (...)

Bevin M.B. Newman, Giovanna M. Cinelli, Kenneth J. Nunnenkamp, Peter J. Wang, Sébastien J. Evrard, Yizhe Zhang The Chinese MOFCOM publishes the final rules on the national security review of foreign investment in national companies

92

China has published new rules to implement the national security review that will be conducted as part of the review of mergers and acquisitions by foreign investors and involving Chinese companies. These rules provide for review and potential rejection of acquisitions of Chinese companies by (...)

Bevin M.B. Newman, Giovanna M. Cinelli, Kenneth J. Nunnenkamp, Peter J. Wang, Sébastien J. Evrard, Stephen Harris, Yizhe Zhang The Chinese State Council publishes a notice detailing its national security review procedure for the acquisition of domestic companies by foreign investors

887

The State Council of the People’s Republic of China has published a notice detailing its national security review («NSR») procedure for the acquisition by foreign investors of domestic Chinese companies («NSR Notice»). The NSR Notice, which implements Article 31 of the PRC Anti-Monopoly Law, will be (...)

Send a message